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M.R.H.M. van Sambeek,3 J. Klein1 and D. Poldermans1*Departments of 1Anaesthesiology, Erasmus MC, Rotterdam, 2Cardiology, Leiden University Medical Center,
Leiden, 3Vascular Surgery, and 4Clinical Epidemiology, Erasmus MC, Rotterdam, The NetherlandsObjectives. To study whether b-blockers reduce in-hospital and long-term mortality in patients with severe left ventricular
dysfunction (LVD) undergoing major vascular surgery.
Design. Observational cohort study.
Materials. Five hundred and eleven patients with severe LVD (ejection fraction!30%) undergoing major non-cardiac
vascular surgery.
Methods. In all patients, cardiac risk factors, medication (including b-blockers), and dobutamine stress echocardiography
(DSE) results were noted prior to surgery. DSE was evaluated for rest and stress-induced new wall motion abnormalities.
Endpoint was in-hospital and long-term mortality. Propensity scores for b-blockers were calculated and regression models
were used to analyse the relation between b-blockers and mortality.
Results. Mean age was 64G11 years and 383 patients (75%) were male. 139 patients (27%) used b-blockers. Stress-
induced ischemia occurred in 82 patients (16%). Median follow-up was 7 years (interquartile range: 3–10). In-hospital and
long-term mortality was observed in 64 (13%) and 171 (33%) patients, respectively. After adjusting for clinical variables,
DSE results and propensity scores, b-blockers were significantly associated with reduced in-hospital and long-term
mortality (OR: 0.18, 95% CI: 0.04–0.74 and HR: 0.38, 95% CI: 0.22–0.65, respectively).
Conclusion. In patients with severe LVD undergoing major vascular surgery, the use of b-blockers is associated with a
reduced incidence of in-hospital and long-term postoperative mortality.Keywords: b-Blockers; Severe left ventricular dysfunction; Major vascular surgery; Dobutamine stress echocardiography;
Prognosis.The prevalence of congestive heart failure in the adult
population in the United States and United Kingdom
has been estimated to be 1.2 and 1.8%, respectively,
and has been demonstrated to be higher among the
older population with prevalence values of 5.5 and
8.0%, respectively, in patients aged 75 years or older.1,2
Both congestive heart failure and coronary artery
disease have been identified as significant predictors
of postoperative morbidity and mortality in patients
undergoing major non-cardiac surgery.3–5 Because
patients who are at increased risk of postoperative
events may benefit from medical treatment or other
preoperative interventions, the identification of these
patients has been an important goal in preoperativeing author. Don Poldermans, MD, PhD, Thoraxcentre,
Erasmus Medical Center, Dr Molewaterplein 40, 3015
, The Netherlands.
: d.poldermans@erasmusmc.nl
0351+ 08 $35.00/0 q 2005 Elsevier Ltd. All rights reserscreening strategies. Tools for preoperative screening
include cardiac risk scores, such as the revised cardiac
risk index, resting echocardiography, and dobutamine
stress echocardiography, which may detect both left
ventricular dysfunction and stress induced myocar-
dial ischemia.4,6,7
b-Blockers are established therapeutic agents for
patients with hypertension and coronary artery
disease. In addition, b-blockers have been shown to
reduce morbidity and mortality in patients with mild,
moderate and severe chronic heart failure.8–10 As a
result, consensus guidelines strongly recommended
the use of b-blockers in heart failure patients, unless
there is a strong contraindication.11,12 Several random-
ized trials have demonstrated that patients with
coronary artery disease benefit from perioperative
b-blocker therapy in terms of reduced postoperative
morbidity and mortality.13,14Eur J Vasc Endovasc Surg 31, 351–358 (2006)
doi:10.1016/j.ejvs.2005.10.018, available online at http://www.sciencedirect.com onved.
H. H. H. Feringa et al.352We conducted this study to assess whether chronic
b-blocker therapy reduces the incidence of in-hospital
and long-term mortality in patients with severe left
ventricular dysfunction undergoingmajor non-cardiac
vascular surgery. In this cohort study, we used
propensity analysis to adjust for selection bias in the
comparison of treatments.Materials and MethodsStudy cohort
Patients who were referred to the Erasmus Medical
Centre between January 1990 and January 2004 for
elective major vascular surgery were routinely
screened for cardiac risk factors and underwent
resting echocardiography and dobutamine stress
echocardiography (DSE) for pre-operative risk strati-
fication. A total of 511 consecutive patients with
markedly decreased left ventricular function were
retrospectively identified and were included in this
study. Left ventricular systolic dysfunction was
defined as an ejection fraction of 30% or less by
preoperative two-dimensional echocardiography, or
as a resting wall motion-score index of 1.70 or more.
Left ventricular end-diastolic and end-systolic
volumes were obtained from the apical four- and
two-chamber views by using the Simpson’s rule
formula, from which the ejection fraction was calcu-
lated. Wall motion score index was calculated accord-
ing to the guidelines of the American Society of
Echocardiography (ASE), using a 16-segment model.15
b-Blocker therapy was recorded when b-blockers
were started at least 1 month prior and continued to at
least 2 months after surgery. Diabetes mellitus was
recorded if patients presented with a fasting glucose
level of R7.0 mmol/L, or in those who required
treatment. Hypertension was recorded if patients
presented with a blood pressure R140/90 mmHg or
if patients were medically treated for hypertension.
Hypercholesterolemia was recorded if patients pre-
sented with a plasma cholesterol level R5.5 mmol/L,
or if patients were taking lipid-lowering agents. Renal
dysfunction was recorded if patients presented with a
serum creatinine level R2.0 mg/dL (177 mmol/L) or
in those who required dialysis. A baseline 12-lead
electrocardiography was obtained and was considered
abnormal in the presence of one or more of the
following; Q-waves, ST-segment depression or
elevation, left ventricular hypertrophy, right or left
bundle branch block and atrial fibrillation. Surgical
procedures included elective aortic abdominal repair,Eur J Vasc Endovasc Surg Vol 31, April 2006lower extremity revascularisation and carotid artery
surgery.Dobutamine stress echocardiography
All patients underwent a resting two-dimensional
precordial echocardiographic examination and a
12-lead electrocardiogram was recorded. Dobutamine
hydrochloride was then administered intravenously
by infusion pump, starting at 5 mg/kg/min for 5 min,
followed by 10 mg/kg/min for 5 min and increasing
by 10 mg/kg/min every 3 min to a maximum of
40 mg/kg/min, and continued for 6 min. The dobuta-
mine infusion was stopped if a target heart rate (85%
of the age and gender corrected maximal heart rate)
was achieved. If the target heart rate was not achieved
and patients had no symptoms or signs of ischemia,
atropine sulphate (0.25–2.0 mg intravenously) was
given while the administration of dobutamine was
continued. Metoprolol was administered (1.0–5.0 mg
intravenously) to reverse the side effects of the
administration of dobutamine or the dobutamine–
atropine combination if the side effects did not revert
spontaneously and quickly. Two experienced investi-
gators performed off-line assessment of echocardio-
graphic images, and were blinded to the clinical data
in order to give an objective interpretation. Using a
standard 16-segment model, wall motion was scored
on a 5-point scale (a score of 1 indicating normal, 2
mild hypokinesis, 3 severe hypokinesis, 4 akinesis,
and 5 dyskinesis) and a wall motion score index was
calculated (total score divided by the number of
segments scored). The results of DSE were considered
positive if new wall-motion abnormalities occurred
(i.e. if wall motion in any segment worsened by R1
grades during the test, with the exception of akinesis
becoming dyskinesis). This criterion was used
consistently during the whole study period.Postoperative outcome
End-point was mortality. In-hospital mortality was
defined as death occurring during postoperative in-
hospital stay or as death occurring after hospital
discharge but within the first 30 days after surgery.
Long-termmortality was defined as death occurring at
any time from day 1 after surgery. Information about
the patient’s vital status was obtained by reviewing
the hospital’s medical records, by approaching the
patient’s general physician and by approaching the
Office of Civil Registry. The date of the last review or
the date that an endpoint was reached was used to
calculate follow-up time. Median follow-up time was
b-Blockers and Surgical Patients with LV Dysfunction 3537 years (interquartile range: 3–10 years). Follow-up
was completed in all patients.Statistical analysis
Continuous data are expressed as mean (GSD) or
median (Ginterquartile range) and compared using
the Student t-test or Mann–Whitney U-test when
appropriate. Categorical data are presented as percent
frequencies and differences between proportions were
compared using the chi-square test with Yates’
correction. The Kaplan–Meier method with log-rank
test was used to compare survival curves in two or
more groups. Because b-blockers were not assigned in
a random fashion and selection bias may distort the
results of our study, a propensity score for b-blockers
was constructed using multiple logistic regression
analyses. Propensity analyses are reliable tools to
correct for selection bias and the rationale for using
propensity scores has been described previously.16,17
A propensity score is generally defined as the
conditional probability of assignment to a particular
treatment given a vector of observed covariates. To
assess the effect of a treatment in a situation in which
randomization is difficult or impossible, propensity
scores are a useful method for matching members of
different groups. Comparisons of different groups
reveal reliable information on the impact of the
treatment of interest with a small residual bias.17
Clinical variables and medication that were indepen-
dently associated with the decision to prescribe
b-blockers (p-value!0.25) were included in the multi-
variate propensity score. Important determinants to
prescribe b-blockers were angina pectoris, previous
myocardial infarction, hypertension, and hypercho-
lesterolemia (p!0.05). Propensity scores ranged from
0.007 to 0.97.
Logistic regression models were used to analyse the
relation between b-blocker therapy and in-hospital
mortality. Cox hazards regression models were used to
analyse the relation between b-blocker therapy and
long-term mortality. In multivariate analyses, adjust-
ments were made for baseline clinical variables, DSE
results, and propensity scores, irrespective of the
significance level in univariate analysis. In order to
reveal possible heterogeneity between intermediate
risk procedures (carotid artery surgery) and high-risk
procedures (abdominal aortic aneurysm repair and
lower extremity revascularisation procedures), an
interaction term was evaluated. Interaction was
considered statistically significant at the 0.05 prob-
ability level. Odds ratios (OR) and hazard ratios (HR)
are given with 95% confidence intervals. For all tests,a p-value!0.05 (two-sided) was considered signifi-
cant. All analyses were performed using SPSS-11.0
statistical software (SPSS Inc., Chicago, Illinois).Results
Mean age was 64G11 years and 383 patients (75%)
were male. A total of 139 patients (27%) were using
chronic b-blockers; 99 patients (71%) used a selective
b-blocker and 40 patients (29%) a non-selective
b-blocker. Selective b-blockers included atenolol (nZ
8), bisoprolol (nZ41) and metoprolol (nZ50). Non-
selective b-blockers included carvedilol (nZ26) and
sotalol (nZ14). Baseline characteristics of the patients
subdivided according to the use of b-blockers are
summarized in Table 1. During preoperative DSE,
heart rate increased from 72G15 beats/min at rest to
132G18 beats/min at peak stress. The maximum dose
of dobutamine infusion was 37.6G8 mg/kg/min.
Atropine was administered in 312 patients (61%) to
achieve target heart rate. The mean wall motion score
index at rest was 2.11G0.37. The mean wall motion
score index at rest was 2.07G0.28 in patients using
beta-blockers and of 2.11G0.36 in patients who did not
(pZ0.52). The mean wall motion score index at peak
stress was 1.80G0.47. Stress induced myocardial
ischemia occurred in 82 patients (16%). No fatal
complications occurred during or immediately after
the stress test. Abdominal aortic repair was performed
in 237 patients (46%), lower extremity revascularisa-
tion in 221 patients (43%), and carotid artery surgery in
53 patients (10%).Postoperative outcome
In-hospital mortality occurred in 64 patients (13%) and
long-term mortality in 171 patients (33%). Univariate
associations between clinical variables and mortality
are summarized in Table 2. Age above 70 years,
previous myocardial infarction, history of stroke or
transient ischemic attack, renal failure and stress
induced myocardial ischemia were significant unad-
justed determinants for in-hospital and long-term
mortality. The use of b-blockers was associated with
a significant reduction of in-hospital and long-term
mortality (OR: 0.24, 95% CI: 0.10–0.58 and HR: 0.49,
95% CI: 0.32–0.75, respectively). Kaplan–Meier esti-
mates for long-term mortality, stratified according to
the use of b-blockers, showed a better survival for
those patients using b-blocker therapy (p!0.001)
(Fig. 1). In multivariate analysis, the relation between
b-blocker therapy and post-operative mortality wasEur J Vasc Endovasc Surg Vol 31, April 2006
Table 1. Baseline characteristics of the 511 patients
b-Blockers (nZ139) No b-blockers (nZ372) p-Value
Age (years) 64G11 65G12 0.35
Male gender 97 (70%) 286 (77%) 0.19
Angina pectoris 53 (38%) 107 (29%) 0.05
Previous myocardial infarction 85 (61%) 182 (49%) 0.02
Previous coronary revascularisation 51 (37%) 62 (17%) !0.001
Previous stroke or transient ischemic attack 26 (19%) 54 (15%) 0.31
Hypertension 88 (63%) 115 (31%) !0.001
Current smoker 42 (30%) 126 (34%) 0.50
Chronic obstructive pulmonary disease 28 (20%) 60 (16%) 0.35
Hypercholesterolemia 57 (41%) 69 (19%) !0.001
Diabetes mellitus 29 (21%) 43 (12%) 0.01
Renal failure 21 (15%) 36 (10%) 0.11
Electrocardiography
Left ventricular hypertrophy 8 (6%) 29 (8%) 0.55
Q-waves 58 (42%) 125 (34%) 0.11
ST-segment changes 39 (28%) 66 (18%) 0.01
Left bundle branch block 8 (6%) 12 (3%) 0.29
Right bundle branch block 6 (4%) 22 (6%) 0.63
Atrial fibrillation 16 (12%) 21 (6%) 0.04
Type of surgery
Abdominal aortic repair 71 (51%) 166 (45%) 0.23
Lower extremity revascularisation 55 (40%) 166 (45%) 0.35
Carotid artery surgery 13 (9%) 40 (11%) 0.76
Cardiac medication
Aspirin 51 (37%) 74 (20%) !0.001
Angiotensin-converting enzyme inhibitors 74 (53%) 141 (38%) 0.002
Calcium channel blockers 65 (47%) 97 (26%) !0.001
Coumarin 38 (27%) 73 (20%) 0.08
Digoxin 15 (11%) 26 (7%) 0.22
Diuretic 44 (32%) 92 (25%) 0.14
Nitrates 66 (48%) 97 (26%) !0.001
Statins 61 (44%) 46 (12%) !0.001
H. H. H. Feringa et al.354adjusted for clinical variables, DSE results and
propensity scores for b-blockers. The use of b-blockers
remained significantly associated with a reduced
incidence of in-hospital and long-term mortality (OR:
0.18, 95% CI: 0.04–0.74 and HR: 0.38, 95% CI: 0.22–0.65,
respectively) (Fig. 2).
In patients using b-blockers (nZ139), we observed
no significant effect of selective b-blockers asTable 2. Univariate predictors of 30-day and long-term mortality
30-Day mortality (nZ64)
Odds ratio (95% CI)
AgeO70 years 2.11 (1.24–3.57)
Male gender 1.52 (0.78–2.95)
Angina pectoris 1.27 (0.73–2.20)
Previous MI 4.19 (2.22–7.92)
Previous stroke or TIA 5.43 (2.06–9.62)
Hypertension 1.61 (0.95–2.73)
Current smoker 0.74 (0.32–1.70)
Hypercholesterolemia 0.53 (0.23–1.21)
Diabetes mellitus 1.00 (0.47–2.12)
Renal failure 4.54 (2.42–8.54)
COPD 1.56 (0.83–2.93)
Abnormal ECG 0.83 (0.49–1.40)
NWMA 3.23 (1.84–5.66)
b-Blockers 0.24 (0.10–0.58)
MI, myocardial infarction; TIA, transient ischemic attack; COPD, chron
new wall motion abnormalities.
Eur J Vasc Endovasc Surg Vol 31, April 2006compared to non-selective b-blockers on postoperative
mortality (in-hospital mortality: OR: 0.4, 95% CI:
0.1–2.0; long-term mortality: HR: 0.7, 95% CI:
0.3–1.4); in multivariate analyses, this association
was also non-significant (in-hospital mortality: OR:
0.6, 95% CI: 0.1–3.5; long-term mortality: HR: 0.6, 95%
CI: 0.3–1.3). Tests for heterogeneity revealed no
evidence for a differential effect of b-blockers inLong-term mortality (nZ171)
p-Value Hazard ratio (95% CI) p-Value
0.006 1.64 (1.21–2.23) 0.002
0.22 1.28 (0.88–1.87) 0.19
0.39 1.32 (0.96–1.82) 0.09
!0.001 3.07 (2.19–4.34) !0.001
!0.001 2.06 (1.42–2.99) !0.001
0.07 1.05 (0.79–1.44) 0.84
0.47 1.15 (0.81–1.65) 0.38
0.22 1.21 (0.85–1.72) 0.31
0.99 1.61 (1.08–2.40) 0.02
!0.001 2.72 (1.84–4.03) !0.001
0.17 1.27 (0.87–1.87) 0.16
0.49 1.74 (1.25–2.43) !0.001
!0.001 4.11 (2.99–5.67) !0.001
0.001 0.49 (0.32–0.75) !0.001
ic obstructive pulmonary disease; ECG, electrocardiogram; NWMA,
Fig. 1. Kaplan–Meier estimates of all-cause mortality,
stratified according to the use of b-blockers. Dashed line
denotes b-blocker use; solid line denotes no b-blocker use.
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(carotid artery surgery) and high-risk procedures
(abdominal aortic aneurysm repair and lower extre-
mity revascularisation) (p-value for interactionZ0.96).Discussion
This study shows that b-blockers improve in-hospital
and long-term survival in patients with severe left
ventricular dysfunction undergoingmajor non-cardiac
vascular surgery. This association was independent of
clinical risk factors, stress induced myocardial ische-
mia during DSE, and propensity scores for b-blockers.
Congestive heart failure has been identified as an
important risk factor for adverse events after major
non-cardiac surgery. In 1977, Goldman developed the
multifactorial cardiac risk index, which allows pre-
operative estimation of cardiac risk in non-cardiac
surgical procedures.3 They demonstrated that clinical
signs of congestive heart failure such as a preoperative
third heart sound and jugular venous distension
were strongly associated with the development of
postoperative life threatening or fatal cardiac compli-
cations. Twelve years later, Lee et al. developed and
validated the revised cardiac risk index, which
included congestive heart failure as an important
predictor for postoperative cardiac events, among
other predictors, such as ischemic artery disease,
high-risk type of surgery, a history of cerebrovasculardisease, insulin therapy for diabetes mellitus, and
preoperative serum creatinine levels of more than
2.0 mg/dL.4 Although decompensated and compen-
sated heart failure have been identified as, respect-
ively, a major and intermediate determinant of
increased perioperative cardiovascular risk, resting
left ventricular dysfunction as measured by invasive
and non-invasive tests has not been demonstrated to
be a consistent predictor of perioperative cardiac
events.18–21 Therefore, the ACC/AHA guidelines for
perioperative cardiovascular evaluation for non-
cardiac surgery do not recommend routine testing of
left ventricular function in patients without a history
of congestive heart failure.6 However, the identifica-
tion of patients with an ejection fraction of 30% or less
might be important, especially because these patients
may benefit from b-blocker therapy.
Large randomized trials have demonstrated the
usefulness of b-blockers in non-surgical patients with
reduced left ventricular function. The MDC-trial
(Metoprolol in Dilated Cardiomyopathy Trial),
MERIT-HF trial (Metoprolol CR/XL Randomized
Intervention Trial in Congestive Heart Failure),
CIBIS-I and II trial (Cardiac Insufficiency Bisoprolol
Study I and II), and COPERNICUS (Carvedilol
Prospective Randomized Cumulative Survival Study
Group), all have demonstrated the benefits of meto-
prolol, bisoprolol and carvedilol for survival in stable
advanced heart-failure patients.22–25 The CAPRI-
CORN study demonstrated that patients with left
ventricular dysfunction following a recent acute
myocardial infarction also benefit from b-blockers
(carvedilol) in addition to angiotensin-converting
enzyme inhibitors.26 Meta-analyses have confirmed
the usefulness of b-blockers in patients with reduced
left ventricular function, demonstrating that
b-blockers reduced all-cause mortality by around
30%.27–29 As a result, consensus guidelines strongly
support and recommended the use of b-blockers in
a-symptomatic to severe symptomatic heart failure
patients, unless there is an absolute contraindication to
the use of these drugs.11,12
Perioperative management of patients with dilated
or hypertrophic cardiomyopathy undergoing major
surgery is aimed at maximizing preoperative hemo-
dynamic status and providing intensive postoperative
medical therapy and surveillance.6 Although random-
ized trials have demonstrated that patients who are at
risk for coronary artery disease and who undergo
major vascular surgery benefit from perioperative
b-blocker therapy in terms of reduced postoperative
morbidity and mortality, limited is known about the
role of b-blocker therapy in patients with left ven-
tricular dysfunction to improve early and long-termEur J Vasc Endovasc Surg Vol 31, April 2006
  OR 95% CI
Propensity score  0.01 (0.00-0.37) 
β-Blocker use 0.18 (0.04-0.74) 
Angina pectoris 0.42 (0.14-1.25) 
Abnormal ECG 0.49 (0.11-2.22) 
Male gender 0.76 (0.26-2.28) 
COPD  0.83 (0.26-2.69) 
NWMA 1.08 (0.35-3.31) 
Smoker 1.52 (0.52-4.45) 
Diabetes mellitus 1.74 (0.49-6.22) 
Hypercholesterolemia 1.78 (0.51-6.24) 
Renal dysfunction 4.30 (1.42-13.02)
Age>70 years 4.42 (1.61-12.13)
Hypertension  6.53 (1.59-26.87)
History of stroke or TIA 7.96 (2.77-22.87)
Previous MI 16.45 (2.74-98.67)
0.0 0.1 1.0 10.0 100.0
Adjusted hazards ratio for early death
 OR 95% CI
Propensity score 0.22 (0.06-0.85) 
β-Blocker use 0.38 (0.22-0.65) 
Angina pectoris 0.69 (0.44-1.07) 
Smoker 1.01 (0.67-1.54) 
COPD  1.06 (0.65-1.73) 
Hypercholesterolemia 1.13 (0.70-1.81) 
Male gender 1.15 (0.72-1.84) 
Diabetes mellitus 1.16 (0.70-1.92) 
Abnormal ECG 1.54 (0.89-2.69) 
History of MI 1.77 (0.94-3.34) 
Age >70 years 1.95 (1.33-2.86) 
Renal dysfunction 2.06 (1.22-3.47) 
History of stroke or TIA 2.17 (1.31-3.58) 
Hypertension  2.23 (1.19-4.15) 
NWMA 2.38 (1.54-3.69) 
0.0 0.1 1.0 10.0
Adjusted hazards ratio for long-term death
A
B
Fig. 2. Multivariate models to predict 30-day (A) and long-term (B) mortality after major vascular surgery. ECG,
electrocardiogram; COPD, chronic obstructive pulmonary disease; NWMA, new wall motion abnormalities; TIA, transient
ischemic attack; MI, myocardial infarction.
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present study, we demonstrated the beneficial effect
of b-blockers on in-hospital and long-term survival in
patients with left ventricular dysfunction, independent
of the presence or absence of coronary artery disease or
other possible confounding factors. These results
suggest that the effect of beta-blockers is not only dueEur J Vasc Endovasc Surg Vol 31, April 2006to its long-term protective effect, but also due to its
myocardial protective effect during the perioperative
period of surgery. Preoperative screening of patients
with left ventricular dysfunction might, therefore, be
recommended. However, randomized controlled trials
should be conducted before recommending this
approach.
b-Blockers and Surgical Patients with LV Dysfunction 357It is known that an increase in cardiac adrenergic
drive is an early compensatory mechanism for the
failing heart and that chronic activation of the
adrenergic nervous system results in increased cardiac
output and heart rate with increased myocardial
oxygen demand, ischemia and oxidative stress. This
may result in histopathologic changes with sub-
sequent ventricular remodeling. b-Blockers reverse
the process of left ventricular remodeling, leading to
improved hemodynamics with favourable effects on
prognosis.30 In addition, b-blockers may also have
beneficial effects through their heart rate regulating,
anti-arrhythmic and anti-inflammatory effects.31–33 We
speculate that the same mechanisms may be respon-
sible for the reduction in postoperative mortality in
patients with left ventricular dysfunction undergoing
major non-cardiac vascular surgery using concomitant
b-blocker therapy. It may take a prolonged period for
b-blockers to exert its cardioprotective effect and,
therefore, b-blockers should be started at least several
weeks before elective major non-cardiac surgery, when
possible.
The major limitation in this study is that b-blockers
were not administered in a randomized controlled
fashion. Selection bias is a major determinant for
distorted results. However, we applied propensity
analysis, which has been shown to be a reliable
method to adjust for selection bias.16,17 Another
limitation which should be considered when inter-
preting the results is that some patients with severe left
ventricular dysfunction and especially those with
extensive co-morbidity, such as renal dysfunction
and chronic obstructive pulmonary disease, were not
referred to our clinic for major surgery, and, therefore,
were not included in our study.
Based on our results we conclude that b-blockers
are independently associated with a reduced inci-
dence of in-hospital and long-term mortality in
patients with severe left ventricular dysfunction.References
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